Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jan 19.

Published in final edited form as: Circulation. 2009 Dec 28;121(2):276–292. doi: 10.1161/CIRCULATIONAHA.109.895771

DOXO-induced cardiomyopathy. A, Echocardiography in control (C) and at 3 and 6 weeks (wks) after the first injection of DOXO. B, Defects in myocyte mechanics and calcium transient in cells isolated from DOXO-treated hearts at 3 weeks. C–E, DOXO administration enhances apoptosis (C: TdT, white) and senescence (D: p16^INK4a, yellow) and decreases proliferation (E: Ki67, green) of cardiomyocytes (α-sarcomeric actin: α-SA, red) in vivo. F, Myocyte number and volume in control and DOXO-treated rats. *^,** P <0.05 vs. C and 3 wks, respectively.

DOXO-induced cardiomyopathy. A, Echocardiography in control (C) and at 3 and 6 weeks (wks) after the first injection of DOXO. B, Defects in myocyte mechanics and calcium transient in cells isolated from DOXO-treated hearts at 3 weeks. C–E, DOXO administration enhances apoptosis (C: TdT, white) and senescence (D: p16^INK4a, yellow) and decreases proliferation (E: Ki67, green) of cardiomyocytes (α-sarcomeric actin: α-SA, red) in vivo. F, Myocyte number and volume in control and DOXO-treated rats. *^,** P <0.05 vs. C and 3 wks, respectively.